Colorectal cancer has served as a genetic and biological paradigm for the evolution of solid
tumors, and these insights have illuminated early detection, risk stratification, prevention …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained
significant clinical attention in oncology due to their central role in cancer pathogenesis …

Colorectal cancer is a heterogeneous disease that develops via stepwise accumulation of
well-characterized genetic and epigenetic alterations. We review the genetic changes …

Breast cancer exhibits the highest global incidence among all tumor types. Regardless of
the type of breast cancer, metastasis is a crucial cause of poor prognosis. Anoikis, a form of …

Understanding the profile of oncogene and tumor suppressor gene mutations with their
interactions and impact on the prognosis of multiple myeloma (MM) can improve the …

The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

Purpose BRAF V600E mutation is seen in 5% to 8% of patients with metastatic colorectal
cancer (CRC) and is associated with poor prognosis. Vemurafenib, an oral BRAF V600 …

The discovery that a subset of human tumours is dependent on mutationally deregulated
BRAF kinase intensified the development of RAF inhibitors to be used as potential …

Purpose: To determine the prevalence and prognostic value of mismatch repair (MMR)
status and its relation to BRAF mutation (BRAF MT) status in metastatic colorectal cancer …